Expert judgement «Correction of hyperkalemia in CKD. Modern possibilities and therapeutic relevance»
- Autores: Mikhailova N.A1
-
Afiliações:
- Edição: Volume 14, Nº 2 (2022)
- Páginas: 82-82
- Seção: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/276251
- DOI: https://doi.org/10.18565/nephrology.2022.2.82-82
- ID: 276251
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Texto integral
Bibliografia
- Михайлова Н.А., Котенко О.Н., Шилов Е.М. Гиперкалиемия: современный взгляд на проблему и возможности терапии (часть 1). Клиническая нефрология. 2017;2:43-48.
- Epstein M., Reaven N.L., Funk S.E., et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am. J. Manag. Care. 2015;21:212-20.
- Sarafidis P.A., Blacklock R., Wood E., et al. Prevalence and factors associated with hyperkalemiain predialysispatients followed in a low- clearance clinic. Clin. J. Am. Soc. Nephrol. 2012;7:1234-41.
- Рубрикатор клинических рекомендаций Минздрава РФ, ID 469, Хроническая болезнь почек, год утверждения 2021. https://cr.minzdrav.gov.ru/recomend/469_2.
- Yildirim T., Arici M. Piskinpasa S., et al. Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern? Ren. Fail. 2012;34(9):1095-9. doi: 10.3109/0886022X.2012.717478.
- Poison M., Lord T.C., Kangethe A., et al. Clinical and economic impact of hyperkalemia in patients with chronic kidney disease and heart failure. J. Manag. Care Spec. Pharm. 2017;23(Suppl. 4-a):S2-9. doi: 10.18553/jmcp.2017.23.4-a.s2a.
Arquivos suplementares
